Drug Trial Radar · NCT07518459
A Study of Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]AZD4144
Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Feb 11, 2026
Primary completion
May 26, 2026
Study completion May 26, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Quotient Sciences
- First posted
- Apr 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study in healthy volunteers aims to explore blood levels and side effects of the test medicine, and look at how it is broken down when injected into a vein or given as a liquid by mouth. The test medicine will be radiolabeled with a small amount of carbon-14 so it can be tracked in the body. This study will take place at one site in Nottingham, United Kingdom, and will enroll 2 groups of 8 healthy men aged 30-65 years.
Conditions
- Healthy Participants
Interventions
[14C]AZD4144 Solution for InfusionDrug
Intravenous, fasted
[14C]AZD4144 Oral SolutionDrug
Oral, fasted
Primary outcomes
What the sponsor says the trial is designed to measure.
- Amount of AZD4144 excreted (Ae)Time frame: Urine and faecal samples collected from pre-dose until up to 216 hours post-dose
- Amount of AZD4144 excreted expressed as a percentage of the radioactive dose administered (Fe)Time frame: Urine and faecal samples collected from pre-dose until up to 216 hours post-dose
- Cumulative amount of AZD4144 excreted (CumAe)Time frame: Urine and faecal samples collected from pre-dose until up to 216 hours post-dose
- Cumulative amount of AZD4144 excreted expressed as a percentage of the radioactive dose administered (CumFe)Time frame: Urine and faecal samples collected from pre-dose until up to 216 hours post-dose
- Area under the curve (AUC) of circulating plasma total radioactivity (TR) accounting for 10% or more of the doseTime frame: Plasma, urine and faecal samples from pre-dose until up to 216 hours post-dose
- 80% or more of the radioactivity recovered in excretaTime frame: Plasma, urine and faecal samples from pre-dose until up to 216 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Ruddington, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.